U.S. pharma giant copyright scrapped two experimental weight loss capsules past calendar year—a the moment-daily tablet, lotiglipron, as a result of elevated liver enzymes along with a twice-day-to-day capsule, danuglipron, resulting from robust side effects—but CEO Albert Bourla has stated the company is determined to “Enjoy and earn” duri